Clinical characteristics of acute primary angle closure following COVID-19 during the Omicron outbreak in China

中国奥密克戎疫情期间COVID-19后急性原发性闭角型青光眼的临床特征

阅读:2

Abstract

The global pandemic of coronavirus disease 2019 (COVID-19) has been associated with diverse ocular manifestations, yet its potential link with acute primary angle closure (APAC) remains poorly characterized, particularly during the Omicron variant wave. The aim of the present study was to explore the clinical characteristics of APAC following COVID-19 infection during the Omicron epidemic period in China. A retrospective comparison was conducted between patients with APAC who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ribonucleic acid within 15 days before APAC onset (post-COVID-19 group; December 2022 to January 2023), and patients with APAC from the same seasonal period before the pandemic (pre-pandemic group; December 2018 to January 2019). The pre-pandemic group comprised 50 eyes of 48 patients, and the post-COVID-19 group comprised 86 eyes of 78 patients. Demographic, clinical and treatment data were compared between the two groups. The post-COVID-19 group exhibited a significantly deeper anterior chamber depth (ACD) and thinner lens. The post-COVID-19 group also exhibited more extensive angle closure with less frequent ciliary body detachment and a lower proportion of patients treated with glucocorticoid eyedrops. Although patients in the post-COVID-19 group presented with a greater ACD than those in the pre-pandemic group, the ACDs of both groups were within the clinically shallow range. This suggests a potential pathophysiological mechanism involving anterior chamber angle obstruction and inflammation, possibly triggered by SARS-CoV-2 infection, rather than pure pupillary block. Therefore, it is recommended that ophthalmologists should be vigilant for APAC in patients post-infection with COVID-19, even in those with only moderately shallow anterior chambers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。